Healthcare Business Review: Celgene Trial Meets Endpoints, Rosetta’s Commercial Intro

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Celgene Corporation’s (NASDAQ:CELG) Abraxane breast cancer treatment for patients suffering from metastatic melanoma met its primary endpoint of “progression-free survival” in a Phase III trial that compared the drug with acarbazine chemotherapy.

Dendreon Corporation (NASDAQ:DNDN) is getting bets from options traders are gambling on support for the firm, as shown by Tuesday’s desire for short puts. At the close, the company had seen approximately 12,000 puts cross the tape, which is around 13 times its average daily put volume, and almost three times the number of Dendreon calls exchanged.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim’s empagliflozin drug reduced blood pressure in patients with Type II diabetes in two Phase IIb evaluations. In addition, the firms’ Analogue insulin performed well in a Phase II study, along with the already-approved Tradjenta for controlling blood sugar levels in elderly patients having type 2 diabetes in three trials.

Rosetta Genomics (NASDAQ:ROSG) announces the commercial intro of the miRview mets assay, which represents its flagship product in the domestic oncology market. miRview mets2 is a diagnostic tool used by clinicians in the evaluation of cancer patients.

Don’t Miss: What’s Next for Pfizer?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business